Abstract: A system and method are disclosed for using a camera image of a user's eye as a visual stimulus for the calibration point in an eyetracking calibration system. A camera image of a user's eye is generated on a user display using an eyetracker. The camera image of the user's eye is used as a visual stimulus of a calibration point. In an embodiment, the center of the pupil of the camera image of the user's eye represents the coordinates of the calibration point on the user display. In another embodiment, the center of the corneal reflection of the camera image of the user's eye represents the coordinates of the calibration point on the user display.

Abstract: A system and method are disclosed for using a camera image of a user's eye as a visual stimulus for the calibration point in an eyetracking calibration system. A camera image of a user's eye is generated on a user display using an eyetracker. The camera image of the user's eye is used as a visual stimulus of a calibration point. In an embodiment, the center of the pupil of the camera image of the user's eye represents the coordinates of the calibration point on the user display. In another embodiment, the center of the corneal reflection of the camera image of the user's eye represents the coordinates of the calibration point on the user display.

Abstract: The present invention relates to a pharmaceutical composition, comprising a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of (i) HDL increasing compounds; (ii) anti-diabetics; (iii) an anti-hypertensive agent; (iv) cholesterol absorption modulator; (v) apo-A1 analogs and mimetics; (vi) renin inhibitors; (vii) thrombin inhibitors; (viii) aldosterone inhibitors; (ix) GLP-1 agonists; (x) glucagon receptor antagonists; (xi) cannabinoid receptor 1 antagonists; (xii) anti-obesity agents; and (xiii) inhibitors of platelet aggregation or, in each case, a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable carrier.